AstraZeneca Archives

Expert Advice 8 Oct 2019

Why Good Teamwork is Key to Biotech Success

Teamwork is important throughout the development of a company, but never more so than in the early stages of a startup. Charlotte Edenius, co-founder and VP Business and Clinical development…

October 8, 2019 - 10 minutesmins - By Helen Albert

cardiology astrazeneca novartis cardiovascular disease

News and Trends 5 Sep 2019

Top Cardiology Biotech News from the ESC Conference 2019

Many cardiology companies and academics gathered in Paris earlier this week to showcase their latest research into cardiovascular diseases. Read on for a roundup of the most exciting cardiology news…

September 5, 2019 - 4 minutesmins - By Jonathan Smith

ovarian cancer astrazeneca merck lynparza dna repair

News and Trends 19 Jun 2019

EU Gives Lynparza Green Light as First-Line Ovarian Cancer Treatment

The DNA damage repair drug olaparib (Lynparza), developed by AstraZeneca and Merck, has been approved by the EU as a first-line treatment preventing the return of ovarian cancer after initial…

June 19, 2019 - 3 minutesmins - By Jonathan Smith

In Depth 9 Apr 2018

Are PD-1 and PD-L1 Checkpoint Inhibitors As Good As We Thought?

Checkpoint inhibitors, especially those targeting PD-1 and PD-L1, are exploding in popularity. But how much of it is hype? The pipelines of biotech and pharma are filling up with combination therapies…

April 9, 2018 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 5 Mar 2018

Danish Biotech Starts Phase III Atopic Dermatitis Trial With Failed Asthma Treatment

Danish biotech LEO Pharma started a Phase III trial in atopic dermatitis with an antibody that AstraZeneca dropped after failing two Phase III trials in asthma. LEO Pharma is taking…

March 5, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 28 Feb 2018

Yet Another Checkpoint Inhibitor Goes to Trial with Bavarian Nordic’s Cancer Vaccine

Bavarian Nordic and AstraZeneca collaborate on a treatment that uses a cancer vaccine along with a checkpoint inhibitor to treat colorectal and pancreatic cancer. Notably, this is the third checkpoint…

February 28, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 26 Feb 2018

AstraZeneca Collaborates With Swedish Biotech To Speed Up Drug Development

AstraZeneca collaborates with Swedish firm Pelago Bioscience to develop assay that increases the speed and efficiency of drug development. Pelago, a Karolinska Institute spin-off, studies the interactions between a drug…

February 26, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 21 Feb 2018

FDA Approves AstraZeneca’s Lung Cancer Treatment after Rejecting Merck and Pfizer’s

The FDA approval will give AstraZeneca a competitive advantage in the lung cancer treatment market over Merck KGaA & Pfizer, who received rejections for a similar treatment. AstraZeneca received FDA approval for…

February 21, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 15 Jan 2018

The FDA Gives AstraZeneca’s Breast Cancer Drug the Go-Ahead

The UK big pharma company's Lynparza will be for women with advanced breast cancer that is specifically caused by mutations in the BRCA gene. Global pharma giant AstraZeneca focuses on…

January 15, 2018 - 3 minutesmins - By Alex Dale

News and Trends 2 Nov 2017

AstraZeneca and Moderna want to beat Novartis at Treating Heart Failure

AstraZeneca will work with Moderna Therapeutics to bring together to the market an mRNA version of Novartis' failed heart failure drug Serelaxin. AstraZeneca has signed a deal with US biotech Moderna Therapeutics to co-develop and co-commercialize…

November 2, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Oct 2017

Leading Pharma-Academic Partnership Unravels the Mystery of a Major Cancer Gene

The PTEN gene controls cell growth and behavior, with its loss implicated in cancer. AstraZeneca and Babraham have collaborated to improve our understanding of how this happens. The Babraham Institute, Cambridge, UK…

October 20, 2017 - 2 minutesmins - By Alex Dale

In Depth 17 Oct 2017

Blockbuster Potential: How Biotech is Paving the Way to Clear Skin from Psoriasis

Though the psoriasis market is teeming with effective products, companies have developed ways to devise new, more effective modes of treatment. Psoriasis is a common autoimmune disorder that affects the…

October 17, 2017 - 7 minutesmins - By Diana Kwon

imfinzi astrazeneca breakthrough designation

News and Trends 11 Sep 2017

UPDATE: AstraZeneca’s Checkpoint Inhibitor Could be a Lung Cancer Blockbuster

UPDATE: 11/09/2017: AstraZeneca has presented impressive results at ESMO that show Imfinzi adding 11 months to patient survival, or decreasing the risk of progression by 48%, in Stage 3 NSCLC.…

September 11, 2017 - 2 minutesmins - By Evelyn Warner

Circassia pharmaceuticals astrazeneca pulmonary disease

News and Trends 7 Sep 2017

Circassia Moves Away from a Failed Allergy Pipeline with Phase III Success

Circassia has positive Phase III results from its respiratory pipeline, great news for the company after abandoning its allergy immunotherapies due to clinical failure. Circassia Pharmaceuticals, based in Oxford, has…

September 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Astrazeneca Ethris mRNA Therapy MedImmune Edited

News and Trends 21 Aug 2017

AstraZeneca Teams Up with German Biotech to Develop mRNA Therapy

AstraZeneca and its R&D arm MedImmune have partnered with Munich-based Ethris to use its mRNA technology to develop treatments for respiratory disease. Ethris, located in the Munich biotech hub of…

August 21, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

astrazeneca imfinzi durvalumab tremelimumab

News and Trends 27 Jul 2017

AstraZeneca Misses Endpoint in Big Checkpoint Inhibitor Combo Trial

AstraZeneca has announced its Phase III trial with durvalumab and tremelimumab has failed to achieve better results than standard chemotherapy in lung cancer. AstraZeneca's MYSTIC study was evaluating a combination…

July 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 3 May 2017

Unexpected Side Effects: Are we Ready for the Rise of Immunotherapies?

As immunotherapies are moving from large academic centers to clinics across the world, doctors are realizing that releasing the breaks of the immune system comes with serious risks - and…

May 3, 2017 - 4 minutesmins - By Melanie De Almeida

News and Trends 27 Apr 2017

Heptares Finds New GPCR Target to Treat Pain, Cancer and Inflammation

Heptares Therapeutics has published the detailed structure and mechanism of action of a difficult-to-target GPCR protein with great therapeutic prospects. Heptares Therapeutics has published today in Nature new insights into…

April 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Apr 2017

How is Biotech Transforming Pharma’s R&D Model?

Since the early 2000s, pharma has undergone a major reorganization. What roles do strategic alliances and acquisitions play in this new model? For almost two centuries, medicinal products have brought…

April 6, 2017 - 4 minutesmins - By External Contributor

Heptares AstraZeneka AZD4635 checkpoint inhibitor

News and Trends 5 Apr 2017

Heptares Takes Home €11M for its Next-Generation Checkpoint Inhibitor

Heptares Therapeutics has achieved a new milestone in its immuno-oncology collaboration with AstraZeneca triggering an €11M payment from AstraZeneca. Heptares has announced the wrap-up of its preclinical programme for a new checkpoint inhibitor, AZD4635…

April 5, 2017 - 3 minutesmins - By Melanie De Almeida

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

View all companies A-Z

Find new scientific partnerships. Create a free IN-PART account

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inova, the leading platform for biopharma partnering